Malaysia Automated Re-Registration Route: Seven Eligibility Conditions

1. Key takeaways

The Automated Re-Registration Route is a function of MeDC@St 2.0 and later versions that allows eligible registration holders to renew without passing through the standard review route. The MDA announcement dated 10 July 2026, Revision 2, states that the route has applied since 13 July 2026. Eligibility is conditional rather than automatic: seven conditions must all be satisfied at the point of submission, and failure of any single condition returns the file to the standard path. The route is best understood as an administrative fast lane for files that are already in good standing, not as a relaxation of the renewal requirements themselves.

• All seven conditions must be met simultaneously; there is no partial eligibility.
• The holder must have a valid manufacturer licence or AR licence.
• There must be no ongoing or pending change notification or change of ownership application.
• The registration must be valid and within the one-year window before expiry.
• The original registration must have been obtained through full assessment or the verification route.
• A valid CAB certificate must be held, and the registration must not be rejected, suspended or revoked.
• The information submitted must be consistent with the latest MDA approved record.

2. Legal basis

The route is established through the MDA announcement titled Automated Re-Registration Guide, published on the MedCast platform on 10 July 2026 as Revision 2, with an implementation date of 13 July 2026. It operates within the existing re-registration framework and relies on the registration data held in MeDC@St 2.0 and later versions, which is also the source of the one-year window before expiry that governs eligibility. Fees remain those prescribed in the Fifth Schedule to the Medical Device Regulations 2012 as amended by P.U.(A) 330/2025, so the automated route changes the review path but not the fee schedule. The requirement that the original registration have been obtained through full assessment or the verification route ties eligibility to the substantive basis on which the device was first registered, which means the route cannot be used to launder an assessment that was never completed. The obligation to hold a valid CAB certificate in turn links eligibility to the ongoing conformity assessment relationship rather than to the registration record alone.

3. Expert insights

The seven conditions look like a checklist, and in one sense they are, but three of them behave differently from the rest. Licence validity, registration validity and CAB certificate validity are all dated facts that can lapse between the moment eligibility is assessed and the moment the application is submitted. The prohibition on pending change notifications or change of ownership applications is a state condition that can be created by an unrelated internal decision, for example a routine labelling update initiated by a commercial team. The requirement that submitted information match the latest MDA approved record is a consistency condition that fails silently when a product has evolved without the corresponding regulatory step. Together these conditions mean that eligibility is a status to be maintained continuously, not a test performed once at renewal.

The benefits of the route are real but narrower than they first appear. There is no prescribed review timeline, which means the timing depends on how quickly the applicant completes the required steps, so the route rewards administrative readiness rather than technical argument. The registration number does not change, and validity continues from the original certificate, which preserves continuity for import and supply purposes. Certain limited fields can be updated, while all other data must remain consistent with the MDA approved record. That combination is well suited to a stable product with a clean change history, and poorly suited to a product whose file has drifted.

The boundaries define the practical risk. Information outside the limited fields cannot be changed, and preclinical reports covering biocompatibility, stability and validation cannot be updated through the route. Any modification that amounts to a substantive change to the registered device must go through a change notification and be approved first. A manufacturer that uses the automated route as an opportunity to bring a stale file up to date will find the route closed to it, because the very act of updating beyond the permitted fields is what disqualifies the file. The correct sequence is to resolve substantive changes through the change notification process and then renew, on whichever route the resulting status permits.

4. Practical recommendations

• Turn the seven eligibility conditions into an annual compliance self-check and run it quarterly, rather than reviewing them only when the renewal window opens.
• Track pending change notifications and change of ownership applications as a standing item, since either one suspends eligibility while it remains unresolved.
• Monitor CAB certificate expiry separately from registration expiry, as the two dates are independent and both are conditions of eligibility.
• Keep the submitted product information aligned with the latest MDA approved record, and route any divergence through a change notification before renewal.
• Identify in advance which fields fall within the permitted updates, and treat everything else as fixed for the purposes of the automated route.
• Exclude biocompatibility, stability and validation reports from the renewal package, and resolve any update to those reports through change control.
• Maintain the CAB certificate and the post-market obligations, including PMS and MPR, on the same footing as before, since the route does not alter them.

5. Verification checklist

• □ The MDA announcement Automated Re-Registration Guide, MedCast, 10 July 2026, Revision 2, with implementation date 13 July 2026, has been reviewed.
• □ All seven eligibility conditions are confirmed as satisfied on the date of submission, not on the date of planning.
• □ The Fifth Schedule to the Medical Device Regulations 2012 and P.U.(A) 330/2025 have been checked for the applicable fee.
• □ CAB certificate validity and registration validity have both been verified against their own expiry dates.
• □ No pending change notification or change of ownership application exists at the point of submission.
• □ Any intended update has been tested against the limited field list, with everything else left consistent with the MDA approved record.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com